News

Zarbee’s launches children’s cough and sleep drink

BY Michael Johnsen

SALT LAKE CITY — Zarbee’s on Wednesday announced the launch of Zarbee’s Nighttime Cough and Sleep Drink, an over-the-counter nighttime cough remedy.

Zarbee’s Nighttime Cough and Sleep Drink is made from antioxidant-rich buckwheat honey, which recent clinical studies have shown is more effective at relieving coughs associated with colds and upper respiratory illnesses than dextromethorphan or diphenhydramine, the company claimed.

In addition to buckwheat honey, Zarbee’s Nighttime Cough and Sleep Drink contains immune-boosting vitamin C, zinc and elderberry and a small amount of melatonin. Zarbee’s Nighttime Cough and Sleep Drink is gluten free, contains no alcohol, drugs or dyes, has no side effects and carries no risk of overdose.


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

APhA urges Americans to talk to pharmacists about diabetes

BY Alaric DeArment

WASHINGTON — The American Pharmacists Association is marking American Pharmacists Month by pushing people to work with their pharmacists to combat and control diabetes.

The APhA is promoting services that pharmacists can provide, such as medication therapy management, counseling on physical activity and nutrition, blood-glucose monitoring and guidance on healthy behavior and health maintenance.

Nearly 26 million people, or 8.3% of the population, have diabetes, according to the Centers for Disease Control and Prevention. In addition, an estimated 79 million people ages 20 years and older have prediabetes.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

FDA to review Merck, Ariad drug for bone, soft-tissue sarcomas

BY Alaric DeArment

WHITEHOUSE STATION, N.J. — The Food and Drug Administration has accepted a regulatory approval application from Merck and Ariad Pharmaceuticals for a new drug to treat soft-tissue and bone cancers, the drug makers said Wednesday.

The FDA is expected to complete its review of ridaforolimus for soft-tissue and bone sarcomas in patients who have shown a favorable response to chemotherapy by second quarter 2012.

Sarcomas are cancers of the body’s connective tissues, and treatment options remain limited, the companies said.


Interested in this topic? Sign up for our weekly Retail Health Provider e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?